The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Evolving CLL treatments: creating choices and igniting discussions
Deborah Henderson, chronic lymphocytic leukemia (CLL) patient advocate and journalist, is joined by Michael Hallek, MD, PhD from the University of Cologne, Cologne, Germany to talk about his session on the ‘Evolution of Treatment in Relapsed/Refractory CLL’ at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 held in New York, NY. During this popular session, Prof. Hallek discussed how the novel combination of therapies has allowed long-term remission to be an achievable treatment aim. It was apparent during the session though, that there is a lack of consensus among physicians regarding what the best treatment options are and what the treatments goals are for physicians. As an experienced patient advocate, Deborah moves the discussion towards medical inequalities that exist in CLL treatment.
